{"url_path":"/sec/gmrs/8-k/2026-09-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1898718/0001104659-26-107124-index.html","accession_number":"0001104659-26-107124","cik":"0001898718","ticker":"GMRS","issuer_name":"GMR Solutions Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1898718/0001104659-26-107124-index.html","primary_entity_key":"0001898718","primary_entity_name":"GMR Solutions Inc."},"word_count":311,"has_tables":true,"body_markdown":"**Item 8.01****Other Events.**\n\n \n\nOn September 11, 2026,\nGlobal Medical Response, Inc. (“GMR, Inc.”), a subsidiary of GMR Solutions Inc. (the “Company”), announced\nit has received binding commitments from lenders sufficient to complete a repricing transaction with respect to GMR, Inc.’s\nexisting first lien term loan facility. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by\nreference.\n\n \n\nThe repricing\ntransaction is expected to amend GMR, Inc.’s existing first lien term loan. In connection with the repricing transaction, GMR,\nInc. expects to voluntarily prepay approximately $200 million of the outstanding first lien term loan. The amended term loan is expected to bear interest at a lower applicable interest rate margin than GMR, Inc.’s existing term loan. The applicable\ninterest rate margin to the SOFR rate published by CME Group Benchmark Administration Limited (“SOFR”) will\ndecrease from +3.25% to +2.75%, representing a reduction of approximately 50 basis points. The Company expects the repricing\ntransaction and related debt repayment to result in approximately $28 million of annual cash interest expense savings.\n\n \n\nThe Company believes the\ntransaction is consistent with its capital allocation strategy of using cash generated by the business to reduce indebtedness, lower borrowing\ncosts and support its long-term deleveraging objectives.\n\n \n\nThe Company currently expects\nthe repricing transaction to close on or about September 17, 2026, subject to the execution of definitive documentation and satisfaction\nof customary closing conditions.\n\n \n\nThis Current Report on Form\n8-K contains forward-looking statements, including statements regarding the expected consummation, timing and benefits of the repricing\ntransaction. Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of various\nrisks and uncertainties, including the failure to satisfy customary closing conditions or complete the transaction on the anticipated\nterms or timetable. The Company undertakes no obligation to update any forward-looking statements except as required by law."}